Last 12 months
Inside the activity.
6 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 3 | 0 |
| Dec 2025 | 3 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 26, 2023 Filed Jul 7, 2023 19:02 UTC |
MARSHALL ALLANDirector · Chief Executive Officer · 10% owner
|
PurchaseCommon Stock | 23,952 | $2.43 | $58,251.26 |
DisclosureSEC source: 0001477932-23-005103 · form4.xml · nonDerivative · entry 3 MARSHALL ALLAN · CIK 0001279925 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,642,803 F1 · price: This transaction was executed in multiple trades at prices ranging from $2.25 to $2.45. The price reported above reflects the average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 23, 2023 Filed Jul 7, 2023 19:02 UTC |
MARSHALL ALLANDirector · Chief Executive Officer · 10% owner
|
PurchaseCommon Stock | 7,893 | $2.39 | $18,848.48 |
DisclosureSEC source: 0001477932-23-005103 · form4.xml · nonDerivative · entry 2 MARSHALL ALLAN · CIK 0001279925 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,618,851 F1 · price: This transaction was executed in multiple trades at prices ranging from $2.25 to $2.45. The price reported above reflects the average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 22, 2023 Filed Jul 7, 2023 19:02 UTC |
MARSHALL ALLANDirector · Chief Executive Officer · 10% owner
|
PurchaseCommon Stock | 100 | $2.28 | $227.50 |
DisclosureSEC source: 0001477932-23-005103 · form4.xml · nonDerivative · entry 1 MARSHALL ALLAN · CIK 0001279925 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,610,958 F1 · price: This transaction was executed in multiple trades at prices ranging from $2.25 to $2.45. The price reported above reflects the average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 22, 2023 Filed May 23, 2023 20:22 UTC |
MARSHALL ALLANDirector · CHIEF EXECUTIVE OFFICER · 10% owner
|
PurchaseCommon Stock | 22,776 | $3.41 | $77,739.04 |
DisclosureSEC source: 0001415889-23-008591 · form4-05232023_080529.xml · nonDerivative · entry 1 MARSHALL ALLAN · CIK 0001279925 · Director · CHIEF EXECUTIVE OFFICER · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,610,858 Read SEC document |
| March 17, 2023 Filed Mar 20, 2023 20:17 UTC |
MARSHALL ALLANDirector · CHIEF EXECUTIVE OFFICER · 10% owner
|
PurchaseCommon Stock | 4,095 | $4.41 | $18,074.92 |
DisclosureSEC source: 0001415889-23-005213 · form4-03202023_080303.xml · nonDerivative · entry 3 MARSHALL ALLAN · CIK 0001279925 · Director · CHIEF EXECUTIVE OFFICER · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,588,082 Read SEC document |
| March 16, 2023 Filed Mar 20, 2023 20:17 UTC |
MARSHALL ALLANDirector · CHIEF EXECUTIVE OFFICER · 10% owner
|
PurchaseCommon Stock | 4,572 | $4.48 | $20,479.36 |
DisclosureSEC source: 0001415889-23-005213 · form4-03202023_080303.xml · nonDerivative · entry 2 MARSHALL ALLAN · CIK 0001279925 · Director · CHIEF EXECUTIVE OFFICER · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,583,987 Read SEC document |
| March 15, 2023 Filed Mar 20, 2023 20:17 UTC |
MARSHALL ALLANDirector · CHIEF EXECUTIVE OFFICER · 10% owner
|
PurchaseCommon Stock | 4,334 | $4.33 | $18,754.08 |
DisclosureSEC source: 0001415889-23-005213 · form4-03202023_080303.xml · nonDerivative · entry 1 MARSHALL ALLAN · CIK 0001279925 · Director · CHIEF EXECUTIVE OFFICER · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,579,415 Read SEC document |
| December 16, 2022 Filed Jan 11, 2023 21:56 UTC |
MARSHALL ALLANDirector · CHIEF EXECUTIVE OFFICER · 10% owner
|
PurchaseCommon Stock | 4,578 | $3.59 | $16,435.02 |
DisclosureSEC source: 0001415889-23-000829 · form4-01112023_090113.xml · nonDerivative · entry 3 MARSHALL ALLAN · CIK 0001279925 · Director · CHIEF EXECUTIVE OFFICER · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,575,081 Read SEC document |
| December 15, 2022 Filed Jan 11, 2023 21:56 UTC |
MARSHALL ALLANDirector · CHIEF EXECUTIVE OFFICER · 10% owner
|
PurchaseCommon Stock | 2,725 | $3.66 | $9,973.50 |
DisclosureSEC source: 0001415889-23-000829 · form4-01112023_090113.xml · nonDerivative · entry 2 MARSHALL ALLAN · CIK 0001279925 · Director · CHIEF EXECUTIVE OFFICER · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,570,503 Read SEC document |
| December 14, 2022 Filed Jan 11, 2023 21:56 UTC |
MARSHALL ALLANDirector · CHIEF EXECUTIVE OFFICER · 10% owner
|
PurchaseCommon Stock | 10,000 | $3.75 | $37,500.00 |
DisclosureSEC source: 0001415889-23-000829 · form4-01112023_090113.xml · nonDerivative · entry 1 MARSHALL ALLAN · CIK 0001279925 · Director · CHIEF EXECUTIVE OFFICER · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,567,778 Read SEC document |
| December 09, 2022 Filed Dec 13, 2022 22:48 UTC |
MARSHALL ALLANDirector · CHIEF EXECUTIVE OFFICER · 10% owner
|
PurchaseCommon Stock | 12,000 | $4.11 | $49,320.00 |
DisclosureSEC source: 0001415889-22-012507 · form4-12132022_101242.xml · nonDerivative · entry 1 MARSHALL ALLAN · CIK 0001279925 · Director · CHIEF EXECUTIVE OFFICER · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,557,778 Read SEC document |
| December 01, 2022 Filed Dec 5, 2022 20:24 UTC |
MARSHALL ALLANDirector · CHIEF EXECUTIVE OFFICER · 10% owner
|
PurchaseCommon Stock | 18,475 | $3.96 | $73,161.00 |
DisclosureSEC source: 0001415889-22-012031 · form4-12052022_081255.xml · nonDerivative · entry 1 MARSHALL ALLAN · CIK 0001279925 · Director · CHIEF EXECUTIVE OFFICER · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,545,778 Read SEC document |
| September 30, 2022 Filed Nov 17, 2022 21:02 UTC |
Dugan LawrenceDirector
|
GrantStock Option Grant (right to buy) · Derivative | 50,000 | $0.00 Strike: $3.87 | $0.00 |
DisclosureSEC source: 0001415889-22-011484 · form4-11172022_091153.xml · derivative · entry 1 Dugan Lawrence · CIK 0001864559 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2027-09-30 F1 · derivative.exercise_date: The option provides for vesting in equal monthly installments for the two-year period starting on July 1, 2022 and ending on July 1, 2024; therefore, on the grant date of September 30, 2022, such options immediately vested for 3 months and thereafter will continue to vest on a monthly basis for the succeeding 21 months. F1 · derivative.expiration_date: The option provides for vesting in equal monthly installments for the two-year period starting on July 1, 2022 and ending on July 1, 2024; therefore, on the grant date of September 30, 2022, such options immediately vested for 3 months and thereafter will continue to vest on a monthly basis for the succeeding 21 months. Read SEC document |
| September 30, 2022 Filed Nov 17, 2022 16:07 UTC |
Williams Thomas CharlesDirector
|
GrantStock Option Grant (right to buy) · Derivative | 50,000 | $0.00 Strike: $3.87 | $0.00 |
DisclosureSEC source: 0001415889-22-011491 · form4-11172022_091133.xml · derivative · entry 1 Williams Thomas Charles · CIK 0001474253 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2027-09-30 F1 · derivative.exercise_date: The option provides for vesting in equal monthly installments for the two-year period starting on July 1, 2022 and ending on July 1, 2024; therefore, on the grant date of September 30, 2022, such options immediately vested for 3 months and thereafter will continue to vest on a monthly basis for the succeeding 21 months. F1 · derivative.expiration_date: The option provides for vesting in equal monthly installments for the two-year period starting on July 1, 2022 and ending on July 1, 2024; therefore, on the grant date of September 30, 2022, such options immediately vested for 3 months and thereafter will continue to vest on a monthly basis for the succeeding 21 months. Read SEC document |
| September 30, 2022 Filed Nov 17, 2022 21:16 UTC |
Salkind GeneDirector · 10% owner
|
GrantStock Option Grant (right to buy) · Derivative | 50,000 | $0.00 Strike: $3.87 | $0.00 |
DisclosureSEC source: 0001415889-22-011497 · form4-11172022_091143.xml · derivative · entry 1 Salkind Gene · CIK 0001592481 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2027-09-30 F1 · derivative.exercise_date: The option provides for vesting in equal monthly installments for the two-year period starting on July 1, 2022 and ending on July 1, 2024; therefore, on the grant date of September 30, 2022, such options immediately vested for 3 months and thereafter will continue to vest on a monthly basis for the succeeding 21 months. F1 · derivative.expiration_date: The option provides for vesting in equal monthly installments for the two-year period starting on July 1, 2022 and ending on July 1, 2024; therefore, on the grant date of September 30, 2022, such options immediately vested for 3 months and thereafter will continue to vest on a monthly basis for the succeeding 21 months. Read SEC document |
| March 30, 2022 Filed Apr 1, 2022 18:42 UTC |
Salkind GeneDirector · 10% owner
|
PurchaseCommon Stock | 125,000 | $4.00 | $500,000.00 |
DisclosureSEC source: 0001477932-22-001943 · form4.xml · nonDerivative · entry 1 Salkind Gene · CIK 0001592481 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Trustee Disclosed balance after: 125,000 F1 · balance_after: 125,000 shares were purchased at $4.00 per share in a private transaction through the Marital Trust GST subject U/W/O Leopold Salkind Gene Salkind, Trustee and considered indirect ownership of Gene Salkind Read SEC document |
| July 21, 2021 Filed Aug 30, 2021 19:24 UTC |
Williams Thomas CharlesDirector
|
GrantOption Grant · Derivative | 50,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001279925-21-000007 · primary_doc.xml · derivative · entry 1 Williams Thomas Charles · CIK 0001474253 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires not disclosed F1 · derivative.exercise_price: 50,000 options are vested and shall be exercisable for a price of $4.18 per option share for 2 years from July 21, 2021 (the "Grant Date"); such options shall vest on a monthly basis over a one year period and be exercisable for a price of $4.18 per option share for two years from the Grant Date. F1 · date: 50,000 options are vested and shall be exercisable for a price of $4.18 per option share for 2 years from July 21, 2021 (the "Grant Date"); such options shall vest on a monthly basis over a one year period and be exercisable for a price of $4.18 per option share for two years from the Grant Date. F1 · price: 50,000 options are vested and shall be exercisable for a price of $4.18 per option share for 2 years from July 21, 2021 (the "Grant Date"); such options shall vest on a monthly basis over a one year period and be exercisable for a price of $4.18 per option share for two years from the Grant Date. F1 · derivative.exercise_date: 50,000 options are vested and shall be exercisable for a price of $4.18 per option share for 2 years from July 21, 2021 (the "Grant Date"); such options shall vest on a monthly basis over a one year period and be exercisable for a price of $4.18 per option share for two years from the Grant Date. F1 · derivative.expiration_date: 50,000 options are vested and shall be exercisable for a price of $4.18 per option share for 2 years from July 21, 2021 (the "Grant Date"); such options shall vest on a monthly basis over a one year period and be exercisable for a price of $4.18 per option share for two years from the Grant Date. Read SEC document |
| July 21, 2021 Filed Aug 30, 2021 23:04 UTC |
MARSHALL ALLANDirector · CEO · 10% owner
|
GrantOption Grant · Derivative | 1,250,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001279925-21-000004 · primary_doc.xml · derivative · entry 1 MARSHALL ALLAN · CIK 0001279925 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,250,000 Underlying: Common Stock · 1,250,000 shares Expires not disclosed F1 · derivative.exercise_price: 1,250,000 options are vested and shall be exercisable for a price of $4.18 per option share for 2 years from July 21, 2021 (the "Grant Date"); such options shall vest on a monthly basis over a one year period and be exercisable for a price of $4.18 per option share for two years from the Grant Date. F1 · date: 1,250,000 options are vested and shall be exercisable for a price of $4.18 per option share for 2 years from July 21, 2021 (the "Grant Date"); such options shall vest on a monthly basis over a one year period and be exercisable for a price of $4.18 per option share for two years from the Grant Date. F1 · price: 1,250,000 options are vested and shall be exercisable for a price of $4.18 per option share for 2 years from July 21, 2021 (the "Grant Date"); such options shall vest on a monthly basis over a one year period and be exercisable for a price of $4.18 per option share for two years from the Grant Date. F1 · derivative.exercise_date: 1,250,000 options are vested and shall be exercisable for a price of $4.18 per option share for 2 years from July 21, 2021 (the "Grant Date"); such options shall vest on a monthly basis over a one year period and be exercisable for a price of $4.18 per option share for two years from the Grant Date. F1 · derivative.expiration_date: 1,250,000 options are vested and shall be exercisable for a price of $4.18 per option share for 2 years from July 21, 2021 (the "Grant Date"); such options shall vest on a monthly basis over a one year period and be exercisable for a price of $4.18 per option share for two years from the Grant Date. Read SEC document |
| July 21, 2021 Filed Aug 30, 2021 23:11 UTC | GrantOption Grant · Derivative | 200,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001279925-21-000005 · primary_doc.xml · derivative · entry 1 Norstrud Andrew James · CIK 0001311402 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires not disclosed F1 · derivative.exercise_price: 200,000 options are vested and shall be exercisable for a price of $4.18 per option share for 2 years from July 21, 2021 (the "Grant Date"); such options shall vest on a monthly basis over a one year period and be exercisable for a price of $4.18 per option share for two years from the Grant Date. F1 · date: 200,000 options are vested and shall be exercisable for a price of $4.18 per option share for 2 years from July 21, 2021 (the "Grant Date"); such options shall vest on a monthly basis over a one year period and be exercisable for a price of $4.18 per option share for two years from the Grant Date. F1 · price: 200,000 options are vested and shall be exercisable for a price of $4.18 per option share for 2 years from July 21, 2021 (the "Grant Date"); such options shall vest on a monthly basis over a one year period and be exercisable for a price of $4.18 per option share for two years from the Grant Date. F1 · derivative.exercise_date: 200,000 options are vested and shall be exercisable for a price of $4.18 per option share for 2 years from July 21, 2021 (the "Grant Date"); such options shall vest on a monthly basis over a one year period and be exercisable for a price of $4.18 per option share for two years from the Grant Date. F1 · derivative.expiration_date: 200,000 options are vested and shall be exercisable for a price of $4.18 per option share for 2 years from July 21, 2021 (the "Grant Date"); such options shall vest on a monthly basis over a one year period and be exercisable for a price of $4.18 per option share for two years from the Grant Date. Read SEC document |
|
| July 21, 2021 Filed Aug 30, 2021 23:18 UTC |
Salkind GeneDirector · 10% owner
|
GrantOption Grant · Derivative | 50,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001279925-21-000006 · primary_doc.xml · derivative · entry 1 Salkind Gene · CIK 0001592481 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires not disclosed F1 · derivative.exercise_price: 50,000 options are vested and shall be exercisable for a price of $4.18 per option share for 2 years from July 21, 2021 (the "Grant Date"); such options shall vest on a monthly basis over a one year period and be exercisable for a price of $4.18 per option share for two years from the Grant Date. F1 · date: 50,000 options are vested and shall be exercisable for a price of $4.18 per option share for 2 years from July 21, 2021 (the "Grant Date"); such options shall vest on a monthly basis over a one year period and be exercisable for a price of $4.18 per option share for two years from the Grant Date. F1 · price: 50,000 options are vested and shall be exercisable for a price of $4.18 per option share for 2 years from July 21, 2021 (the "Grant Date"); such options shall vest on a monthly basis over a one year period and be exercisable for a price of $4.18 per option share for two years from the Grant Date. F1 · derivative.exercise_date: 50,000 options are vested and shall be exercisable for a price of $4.18 per option share for 2 years from July 21, 2021 (the "Grant Date"); such options shall vest on a monthly basis over a one year period and be exercisable for a price of $4.18 per option share for two years from the Grant Date. F1 · derivative.expiration_date: 50,000 options are vested and shall be exercisable for a price of $4.18 per option share for 2 years from July 21, 2021 (the "Grant Date"); such options shall vest on a monthly basis over a one year period and be exercisable for a price of $4.18 per option share for two years from the Grant Date. Read SEC document |
| July 21, 2021 Filed Aug 31, 2021 21:21 UTC |
Dugan LawrenceDirector
|
GrantOption Grant · Derivative | 50,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001864559-21-000001 · primary_doc.xml · derivative · entry 1 Dugan Lawrence · CIK 0001864559 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires not disclosed F1 · derivative.exercise_price: 50,000 options are vested and shall be exercisable for a price of $4.18 per option share for 2 years from July 21, 2021 (the "Grant Date"); such options shall vest on a monthly basis over a one year period and be exercisable for a price of $4.18 per option share for two years from the Grant Date. F1 · date: 50,000 options are vested and shall be exercisable for a price of $4.18 per option share for 2 years from July 21, 2021 (the "Grant Date"); such options shall vest on a monthly basis over a one year period and be exercisable for a price of $4.18 per option share for two years from the Grant Date. F1 · price: 50,000 options are vested and shall be exercisable for a price of $4.18 per option share for 2 years from July 21, 2021 (the "Grant Date"); such options shall vest on a monthly basis over a one year period and be exercisable for a price of $4.18 per option share for two years from the Grant Date. F1 · derivative.exercise_date: 50,000 options are vested and shall be exercisable for a price of $4.18 per option share for 2 years from July 21, 2021 (the "Grant Date"); such options shall vest on a monthly basis over a one year period and be exercisable for a price of $4.18 per option share for two years from the Grant Date. F1 · derivative.expiration_date: 50,000 options are vested and shall be exercisable for a price of $4.18 per option share for 2 years from July 21, 2021 (the "Grant Date"); such options shall vest on a monthly basis over a one year period and be exercisable for a price of $4.18 per option share for two years from the Grant Date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.